Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 77 trials

Late-Stage Pipeline

38%

29 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

34 recruiting3 with results

Enrollment reporting

Analytics

Phase 4
19(26.4%)
Phase 2
16(22.2%)
Phase 1/2
12(16.7%)
Phase 1
10(13.9%)
Phase 3
10(13.9%)
N/A
3(4.2%)
Phase 2/3
2(2.8%)
72Total
Phase 4(19)
Phase 2(16)
Phase 1/2(12)
Phase 1(10)
+3 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (77)

Showing 20 of 77 trials
NCT07133490Phase 2Recruiting

INTERACT Stomach-II

Role: lead

NCT04258943Phase 1/2Active Not Recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Role: lead

NCT06771492Phase 3Active Not Recruiting

Efficacy of Antibiotic Treatment for Patients With Chronic Low Back Pain and Modic Type I Changes - Randomized Placebo-controlled Trial

Role: lead

NCT05762536Phase 2Recruiting

Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

Role: lead

NCT06859957Phase 3Active Not Recruiting

Melatonin for Patients With Chronic Low Back Pain

Role: lead

NCT07108244Not ApplicableEnrolling By Invitation

Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease

Role: lead

NCT04927780Phase 3Active Not Recruiting

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Role: lead

NCT07384624Phase 1/2Not Yet Recruiting

Combining Latency Reversing Agents to Address the HIV Reservoir

Role: lead

NCT06161818Phase 2Recruiting

Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

Role: lead

NCT07260435Phase 3Recruiting

Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer

Role: lead

NCT07254897Not ApplicableNot Yet Recruiting

Long-term Muscle Synthetic Effects of Intradialytic Parenteral Nutrition in Chronic Hemodialysis Patients

Role: lead

NCT05449366Phase 1/2Completed

Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

Role: lead

NCT05228574Phase 4Completed

Treatment of Vascular Stiffness in ADPKD

Role: lead

NCT07114627Recruiting

Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

Role: lead

NCT05870423Phase 1Recruiting

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Role: lead

NCT05652673Not ApplicableRecruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Role: lead

NCT06193525Phase 2Recruiting

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

Role: lead

NCT05682482Phase 3Recruiting

LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

Role: lead

NCT05491616Phase 2Active Not Recruiting

Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

Role: lead

NCT06118710Phase 4Recruiting

Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment

Role: lead